ArticleJournal of market access & health policy2020

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Kevin Bowrin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.